Cunning Capital Partners LP Makes New $1.11 Million Investment in Hims & Hers Health, Inc. $HIMS

Cunning Capital Partners LP bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 34,200 shares of the company’s stock, valued at approximately $1,110,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Flagship Harbor Advisors LLC acquired a new position in Hims & Hers Health during the fourth quarter worth about $28,000. Binnacle Investments Inc acquired a new position in Hims & Hers Health during the third quarter worth about $28,000. Bogart Wealth LLC grew its position in Hims & Hers Health by 235.8% during the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after buying an additional 632 shares during the period. Geneos Wealth Management Inc. acquired a new position in Hims & Hers Health during the first quarter worth about $30,000. Finally, Entrust Financial LLC acquired a new position in Hims & Hers Health during the fourth quarter worth about $47,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $29.02 on Wednesday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. The company has a market capitalization of $6.72 billion, a price-to-earnings ratio of -322.40, a PEG ratio of 50.98 and a beta of 2.37. The company’s 50 day simple moving average is $24.93 and its 200 day simple moving average is $26.91. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). The firm had revenue of $608.10 million for the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.20 EPS. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.04 EPS for the current year.

Analyst Ratings Changes

HIMS has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $25.00 price target on shares of Hims & Hers Health in a report on Tuesday, May 5th. Truist Financial upped their price target on shares of Hims & Hers Health from $18.00 to $23.00 and gave the company a “hold” rating in a report on Friday, May 22nd. Bank of America reduced their price target on shares of Hims & Hers Health from $28.00 to $25.00 and set a “neutral” rating on the stock in a report on Tuesday, May 26th. Evercore set a $24.00 price target on shares of Hims & Hers Health in a report on Tuesday, February 24th. Finally, Morgan Stanley reduced their price target on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $28.70.

Insider Activity at Hims & Hers Health

In related news, Director David B. Wells purchased 48,400 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were bought at an average price of $24.23 per share, with a total value of $1,172,732.00. Following the completion of the purchase, the director directly owned 224,417 shares in the company, valued at approximately $5,437,623.91. This trade represents a 27.50% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Irene Becklund sold 5,529 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $136,511.01. Following the transaction, the insider directly owned 8,752 shares in the company, valued at approximately $216,086.88. This represents a 38.72% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 212,807 shares of company stock valued at $5,473,644 over the last 90 days. 11.76% of the stock is currently owned by insiders.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.